<?xml version='1.0' encoding='utf-8'?>
<document id="30008305"><sentence text="Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A key step towards personalized therapeutics."><entity charOffset="17-29" id="DDI-PubMed.30008305.s1.e0" text="voriconazole" /></sentence><sentence text="Untreated invasive aspergillosis results in high mortality rate in pediatric cancer patients" /><sentence text=" Voriconazole (VORI), the first line of treatment, requires strict dose monitoring because of its narrow therapeutic index and individual variation in plasma concentration levels"><entity charOffset="1-13" id="DDI-PubMed.30008305.s3.e0" text="Voriconazole" /><entity charOffset="15-19" id="DDI-PubMed.30008305.s3.e1" text="VORI" /><pair ddi="false" e1="DDI-PubMed.30008305.s3.e0" e2="DDI-PubMed.30008305.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30008305.s3.e0" e2="DDI-PubMed.30008305.s3.e1" /></sentence><sentence text=" Commonly co-administered drugs; either Esomeprazole (ESO) or Ondansetron (OND) have reported drug-drug interaction with VORI that should adversely alter therapeutic outcomes of the latter"><entity charOffset="40-52" id="DDI-PubMed.30008305.s4.e0" text="Esomeprazole" /><entity charOffset="54-57" id="DDI-PubMed.30008305.s4.e1" text="ESO" /><entity charOffset="62-73" id="DDI-PubMed.30008305.s4.e2" text="Ondansetron" /><entity charOffset="121-131" id="DDI-PubMed.30008305.s4.e3" text="VORI" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e0" e2="DDI-PubMed.30008305.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e0" e2="DDI-PubMed.30008305.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e0" e2="DDI-PubMed.30008305.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e0" e2="DDI-PubMed.30008305.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e1" e2="DDI-PubMed.30008305.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e1" e2="DDI-PubMed.30008305.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e1" e2="DDI-PubMed.30008305.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e2" e2="DDI-PubMed.30008305.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s4.e2" e2="DDI-PubMed.30008305.s4.e3" /></sentence><sentence text=" Although VORI, ESO and OND are co-administered to pediatric cancer patients, the combined effect of ESO and OND on the plasma concentration levels of VORI has not been fully explored"><entity charOffset="10-14" id="DDI-PubMed.30008305.s5.e0" text="VORI" /><entity charOffset="16-19" id="DDI-PubMed.30008305.s5.e1" text="ESO" /><entity charOffset="101-104" id="DDI-PubMed.30008305.s5.e2" text="ESO" /><entity charOffset="151-153" id="DDI-PubMed.30008305.s5.e3" text="VORI" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e0" e2="DDI-PubMed.30008305.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e0" e2="DDI-PubMed.30008305.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e0" e2="DDI-PubMed.30008305.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e0" e2="DDI-PubMed.30008305.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e1" e2="DDI-PubMed.30008305.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e1" e2="DDI-PubMed.30008305.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e1" e2="DDI-PubMed.30008305.s5.e3" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e2" e2="DDI-PubMed.30008305.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30008305.s5.e2" e2="DDI-PubMed.30008305.s5.e3" /></sentence><sentence text=" In this study, an accurate, reliable and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated for simultaneous determination of VORI, ESO, and OND in ultra-low sample volumes (25 μL) of plasma of pediatric cancer patients"><entity charOffset="184-187" id="DDI-PubMed.30008305.s6.e0" text="ESO" /><entity charOffset="178-180" id="DDI-PubMed.30008305.s6.e1" text="VORI" /><pair ddi="false" e1="DDI-PubMed.30008305.s6.e1" e2="DDI-PubMed.30008305.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30008305.s6.e1" e2="DDI-PubMed.30008305.s6.e0" /></sentence><sentence text=" Based on the physicochemical properties of the studied drugs and internal standard, liquid-liquid extraction was successfully adopted with methyl t-butyl ether"><entity charOffset="140-160" id="DDI-PubMed.30008305.s7.e0" text="methyl t-butyl ether" /></sentence><sentence text=" Consistent and reproducible recovery of the three drugs and the internal standard were calculated using plasma and matrix matched samples (RE% &gt; 72" /><sentence text="97%, RSD &lt; 8" /><sentence text="29%)" /><sentence text=" Chromatographic separation was carried out using UPLC with C18 column and a mobile phase of acetonitrile:water:methanol (70:25:5 V/V/V) at 0"><entity charOffset="93-105" id="DDI-PubMed.30008305.s11.e0" text="acetonitrile" /><entity charOffset="112-120" id="DDI-PubMed.30008305.s11.e1" text="methanol" /><pair ddi="false" e1="DDI-PubMed.30008305.s11.e0" e2="DDI-PubMed.30008305.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30008305.s11.e0" e2="DDI-PubMed.30008305.s11.e1" /></sentence><sentence text="3 mL/min" /><sentence text=" Mass spectrometric determination at positive electrospray ionization in the MRM mode was employed" /><sentence text=" The analysis was achieved within 4 min over a linear concentration range of 1" /><sentence text="00-200" /><sentence text="00 ng/mL for the three drugs" /><sentence text=" The assay validity was assessed as per the Food and Drug Administration guidelines for bioanalytical method validation, and satisfactory results were obtained" /><sentence text=" The accuracy and precision were within the acceptable limits for the three drugs in both quality control and incurred plasma samples" /><sentence text=" Matrix effect and process efficiency were investigated in neat solvent, post-extraction matrix, and plasma" /><sentence text=" Correlation of the plasma concentration levels of the three drugs revealed differences from the reported drug-drug interactions" /><sentence text=" This confirmed the need for simultaneous determination of VORI and co-administered drugs in order to achieve optimal therapeutic outcomes"><entity charOffset="59-66" id="DDI-PubMed.30008305.s21.e0" text="VORI" /></sentence><sentence text=" To achieve this, analysis results of this study, genetic polymorphisms in CYP2C19 and clinical data will be used to establish one model incorporating all possible factors that might lead to variation in therapeutic outcomes" /><sentence text="" /></document>